Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?

Canadian Journal of Gastroenterology

Volumn 22, Issue 2, 2008, Pages 149-152

  Turbide, Christian ^a   Soulellis, Constantine A ^b   Deschênes, Marc ^a   Hilzenrat, Nir ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

ALT; Biochemistry; Hepatitis C; Interferon; Myelosuppression; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ANEMIA; ARTICLE; BIOCHEMISTRY; BLOOD TOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEMATOLOGY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LABORATORY TEST; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE; WILCOXON SIGNED RANKS TEST; BLOOD; BLOOD CELL COUNT; COHORT ANALYSIS; DRUG COMBINATION; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BLOOD CELL COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 42449126773     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/213897     Document Type: Article

References (14)

1. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):S237-44.
2. Dormann H, Krebs S, Muth-Selbach U, et al. Rapid onset of hematotoxic effects after interferon alpha in hepatitis C. J Hepatol 2000;32:1041-2. (Lett)
3. Ganser A, Carlo-Stella C, Greher J, Völkers B, Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987;70:1173-9.
4. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-51.
5. Tarumi T, Sawada K, Sato N, et al. Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 1995;23:1310-8.
6. Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998;91:1235-42.
7. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000;31:997-1004.
8. Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin N Am 2004;33(1 Suppl):S25-35.
9. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32:647-53.
10. Conjeevaram HS, Fried MW, Jeffers LJ, et al, for the Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-7.
11. Crovatto M, Pozzato G, Zorat F, et al. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus. Haematologica 2000;85:356-61.
12. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: Consensus guidelines. Can J Gastroenterol 2007;21(Suppl C):25C-34C.
13. Colombatto, P, Civitano L, Oliveri F, et al. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003;8:519-30.
14. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminases. J Hepatol 2003;38:511-7.